Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Multi-drug-resistant tuberculosis future or investigational therapies
Introduction
Overview
Overview
Since new drug resistant tuberculosis have been emerging, the role of future therapies is vital in curbing outbreaks. The new drugs should be more effective than the current regimen and a few drugs in clinical trials have been showing good results.
Future investigations
Future investigations
Principles of future investigations
Any future regimen should satisfy the following principles. [1]
- It should not have more than a maximum duration of 6 months
- The dosing schedule must be simple
- The number of drugs in it should be ideally not more than 3-5 drug each from a different class
- It should have minimum side effect profile so that we could have minimum monitoring
- It should be effective against MDR, XDR and XXDR strains
- It should be administered per orally
- It should have minimum interaction with anti retroviral drugs.
- It should have atleast one new class of drug
New drugs involved in clinical trial for treatment of tuberculosis
| Drug | Phase | Class |
|---|---|---|
| Moxifloxacin | Phase III | Fluoroquinolone |
| Linezolid | Phase II | Oxazolidinone |
| AZD-5847 | Phase II | Oxazolidinone |
| Sutezolid | Phase II | Oxazolidinone |
| Clofazimine | Phase II | Riminophenazine |
| SQ-109 | Phase II | Ethylenediamine |
| PA-824 | Phase IIb | Nitroimidazole |
| Delamanid | Phase III | Nitroimidazole |
| Bedaquiline | Phase III | Diarylquinoline |
| Data provided by WHO[2] | ||
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Â ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]